8:00 am Online Registration & Virtual Coffee Networking
8:45 am Chair’s Opening Remarks
9:00 am Lineage Cell Therapeutics (LCTX): Applying Cell Therapy to Areas of Unmet Medical Need
Synopsis
- Examine OpRegen: An RPE transplant therapy in a Phase 1/2a trial for the treatment of dry-AMD with geographic atrophy
- Explore OPC1: An oligodendrocyte progenitor therapy for acute spinal cord injuries with Orphan and RMAT designations; phase 1 completed
- Discuss VAC2: An allogeneic cancer immunotherapy of antigenpresenting dendritic cells currently in a Phase 1 for oncology
9:30 am Immune-mediated Clearance of Senescence Cells in Oncology
Synopsis
- Explore targeting an immune-oncology target expressed on senescent cells to develop novel senotherapies
- Examine the clinical outcome: Improve SOC in the oncology field by eliminating therapy-induced senescence in cancer
- An exclusive look at Rejuversen’s development of a biological medicine
10:00 am Juvenescence – End-user Insights Driving Healthy Aging Market
Synopsis
- “Lifetime Optimizers”: What sparks their interest?
- Build a broad-based longevity health leader
- Metabolic Switch ketone esters: Our first brand and product created in partnership with the Buck Institute
- The role of science in building trust with end-users
10:45 am Morning Break & Virtual Speed Networking
11:15 am Case Study: Examine Inflammaging & Immune System Dysfunction -Measuring, Tracking & Treating Parkinson’s disease
Synopsis
- Evaluate immune system dysregulation, how it happens and how to treat it
- Discuss the peripheral-central neuroimmune crosstalk in Parkinson’s Disease
- Examine presence versus absence versus dysfunction
- Discuss the clinical correlations with measuring, tracking and treating Parkinson’s Disease
11:45 am Explore Targeted Senolytics: A Higher Selectivity & Safety of Systemic Treatments for Geriatric Syndromes
Synopsis
- Examine novel small molecule designs for targeted, safe and systemic senolysis
- Understand senolytic chronic treatments in geriatric preclinical models with high tolerability amelioration of frailty
- Discuss improvement of age-dependent stem cell exhaustion and loss of regenerative potential recovery of age-related cognitive decline
- Investigate platform to develop novel senolytic drugs to treat various age-related diseases
12:15 pm Discuss Mitochondria Based Therapeutics: A New Class of Novel Therapies for Age-Related Diseases
Synopsis
- Examine how mitochondrial dysfunction underlies many chronic and age-related diseases
- Discover how mitochondrial derived peptides regulate multiple body systems
- Evaluate mitochondria based therapeutics targeting NASH, fibrosis, ARDS, oncology
12:45 pm Lunch & Virtual Networking
1:45 pm Perspectives of Anti-Aging Therapy Targeting Intrinsic DNA Damage Mechanisms
Synopsis
- Explore how aging and longevity of mammals are under strict species specific genetic control
- Since accumulation of cells with damaged DNA is a likely contributor to aging, examine how intrinsic genetically determined mechanisms of DNA damage are expected to be aging drivers
- We hypothesize that activation and expansion of endogenous retroelements occupying collectively nearly half of mammalian genome (‘retrobiome’), can act as intrinsic DNA damage generator
- Discuss how Data in support of this hypothesis defines retrobiome as a prospective target for antiaging therapies will be presented.
2:15 pm Case Study: A Triune Approach to Increasing Longevity – SIWA 318H
Synopsis
- Explore what SIWA 318H is
- Examine SIWA 318H targets
- How does SIWA 318H increase longevity?
2:45 pm Examine Polycystic Kidney Disease as a First Indication for Development of the mTORC1-selective Rapamycin Analog NV-20494
Synopsis
- Explore Kidney cyst formation and its relationship to mTORC1 dysregulation
- Overview of prior experience in polycystic kidney disease with rapamycin and everolimus, and mechanistic considerations related to the importance of mTORC1 selectivity
- Investigate approaches to gathering insight regarding impact of mTORC1 inhibition on endpoints of relevance to longevity
3:15 pm Afternoon Break & Virtual Speed Networking
4:00 pm Explore the Role of Growth Differentiation Factor 11 (GDF11) in Aging & Rejuvenation
Synopsis
- Summary of GDF11 implications in the scientific field Drugifying GDF11
- Examine the influence of GDF11 on brain fate and function and its compelling indications
- Discuss future directions
4:30 pm How to Select the Right Participants for Longevity Clinical Trials?
Synopsis
- Examine why it’s important to select the right participants
- Explore what the considerations are for choosing suitable patient
- Evaluate biotype verses phenotype
- Discuss the clinical relevance and clinical significance of selecting the correct patient pool
5:00 pm Chair’s Closing Remarks
5:15 pm End of Conference
Download the Event Guide for full session details!
